What if treatment could begin before the cancer has a chance to metastasize? That's the question researchers hope to answer with the TRUST-IV clinical trial.

Taletrectinib, is designed to address many of the challenges patients face, including brain metastases and resistance to earlier therapies. New data presented at the 2026 American Association for Cancer Research (AACR) and American Society of Clinical Oncology (ASCO) Annual Meetings continue to build our understanding of how this next-generation targeted therapy performs in both newly diagnosed and previously treated patients.

What to Know About JIDEYTRO upcoming Webinar.